New Approach to Treating “Type 3 Diabetes”
Alzheimer’s disease has been characterized as “type 3 diabetes.” Insulin sensitizers may play a role in treating Alzheimer’s disease and MSDC has developed a new insulin sensitizer that may prevent cognitive decline in people with Alzheimer’s-related dementia.
While the development of Alzheimer’s disease (AD) involves brain cell loss associated with the build-up of abnormal clusters of protein fragments (plaques), and dead and dying nerve cells that contain twisted strands of another protein (tau), other mechanisms also may play a role. Reduced glucose metabolism associated with AD has been tied with a progressive loss of mitochondrial function , and altering mitochondrial dysfunction has been postulated as a target for the treatment of AD together with treatment of insulin resistance—a root cause of type 2 diabetes.,,
Click on this new infographic for more information.